April 18th 2024
Pembrolizumab also demonstrated a disease-free survival benefit vs placebo for patients with clear-cell renal cell carcinoma.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Laurence Albigès, MD, PhD, on Key Findings With Nivolumab/Cabozantinib in Advanced RCC
March 27th 2022Laurence Albigès, MD, PhD, spotlighted 2-year follow-up data from the phase 3 CheckMate 9ER trial, which looked at nivolumab and cabozantinib in patients with previously untreated advanced or metastatic renal cell carcinoma.
Impressions of Data and Results from the CLEAR Trial
Oncologists give their initial impressions about the results of a clinical trial studying doublet combination therapies for advanced renal cell carcinoma.
Background: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert J. Motzer, MD, presents data examined in the article, “Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.”
Combining Surgical and Therapeutic Treatment Options in Evolving Field of RCC
March 16th 2022Gennady Bratslavsky, MD, discusses the ever-changing field of treatment options for renal cell carcinoma at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC.
As Treatment Options Abound, Clinicians Rely on Risk Stratification for Frontline RCC Management
March 15th 2022Primo Nery Lara, Jr., MD, talks treatment of metastatic renal cell carcinoma in the first-line setting at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC.
Choueiri Discusses Results of CLEAR Substudy of Lenvatinib Plus Pembrolizumab in RCC
March 4th 2022At 2022 ASCO GU, Toni K. Choueiri, MD, discussed the CLEAR study and how East Asian patients with renal cell carcinoma derived similar benefit with lenvatinib plus pembrolizumab as the overall trial population.
Atezolizumab/Bevacizumab Demonstrates Comparable OS to Sunitinib for Metastatic RCC
February 22nd 2022The final analysis of the phase 3 IMmotion151 trial did not reveal a significant improvement in overall survival with atezolizumab plus bevacizumab over sunitinib for previously untreated patients with metastatic renal cell carcinoma.